Novartis AG Reports Positive Clinical Trial Results for Rhapsido in Chronic Inducible Urticaria

Novartis AG presented positive results from its RemIND trial, showing that Rhapsido achieved primary endpoints across three subtypes of chronic inducible urticaria. The company also announced a $40 million upfront payment and potential milestone payments worth up to $1.4 billion in collaboration with Orionis Biosciences for molecular glue therapeutics development.

By Sajjl Nooranne Mon, June 22, 2026 at 4:10 PM GMT+3 2 min read · Yahoo Finance · June 22, 2026, 13:10 UTC

Tickers: $NVS

Topics: chronic inducible urticaria Orionis Biosciences collaboration Rhapsido

Read the full article at Yahoo Finance

More World news

Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations Motley Fool · November 12, 2026, 18:56 UTC
The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC
Data I/O Corporation Targets Rapid V-TEK Synergy Realization Amid $80 Million M&A Pipeline Seeking Alpha · November 12, 2026, 18:50 UTC
Leatt Corporation Reports 43% Increase in Q3 Revenue to $20.46 Million Seeking Alpha · November 12, 2026, 18:50 UTC
Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC
California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC